How do you sell the dream without stoking a nightmare?

Running a biotech company means talking up your science just enough to entice investment but not so much that you get crushed by outsized expectations. And that’s harder than it sounds.

STAT sat down with Paul Matteis, co-head of biotech research at Stifel, to talk about the future of neuroscience, the shifting winds of investor sentiment, and why so many biotech companies end up eating their words when their drugs win FDA approval.

“You have to walk the balance right,” Matteis said. “You have to be able to credibly frame the size of the market and also credibly argue why it's going to take some time to build it.”

Read more.